June 12, 2025
Keio University School of Medicine
Keio University Hospital
A research team from the Keio University Hospital Memory Center, led by Dr. Masato Kubota of Minna no Zaitaku Clinic Kokubunji (Assistant Professor at Keio University School of Medicine (Clinical Training) at the time of the research) and Project Professor Daisuke Ito of the Department of Neurology, Keio University School of Medicine, and the Keio University Hospital Memory Center, has demonstrated that the amyloid-beta 42/40 ratio, measured using the simple blood test High Sensitivity Chemiluminescence Enzyme-immunoassay (HISCL®), can identify brain amyloid-beta (Aβ) deposition—a central pathology of Alzheimer's disease (AD)—with high accuracy and at an earlier stage than visual interpretation of amyloid PET scans. This plasma Aβ42/40 is expected to be useful for screening preclinical AD.
These research findings were published in the online edition of the international medical journal Alzheimer's Research & Therapy on June 7, 2025.
Please see below for the full press release.